RxDoctor Payments Data

Joseph Stankus, APRN

Primary Care · High Springs, FLNPI 1629471818

Payments from drug & device makers

$401in general payments, 2019–2025

Across 23 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$112
  • AbbVie$96
  • Abbott$58
  • Novo Nordisk$42
  • GSK$33
  • Boehringer Ingelheim$30
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$39097%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC7$112
AbbVie4$96
Abbott3$58
Novo Nordisk3$42
GSK2$33
Boehringer Ingelheim2$30
AstraZeneca1$18
Pfizer1$13

How this compares

$401 in reported general payments places this provider in the 50th percentile of 725 primary care providers in Florida.

See all primary care providers in Florida

Medicare billing

Part B allowed, 2024
$106,501
Medicare patients
240
Services billed
1,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$140,849
MounjaroTirzepatide77$84,287
EliquisApixaban68$54,978
JardianceEmpagliflozin27$32,986
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$22,600
FarxigaDapagliflozin Propanediol14$19,873
Tresiba Flextouch U-200Insulin Degludec22$17,584
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,715
Tresiba Flextouch U-100Insulin Degludec12$5,442
Levothyroxine Sodium129$1,442
Metoprolol Succinate82$1,431
Duloxetine Hcl31$1,416
Atorvastatin Calcium181$1,327
Omeprazole122$1,090
Amlodipine Besylate162$1,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$42$140,849129 claims
Lilly USA, LLCMounjaro$112$84,28777 claims
PfizerEliquis$13$54,97868 claims
Boehringer IngelheimJardiance$30$32,98627 claims
AstraZenecaFarxiga, Breztri Aerosphere$18$26,58825 claims
GSKTrelegy Ellipta$33$22,60026 claims
AbbVieSynthroid$96$99417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 725 primary care providers in Florida.

Other primary care in High Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →